0
0
0
A bill to provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), and for other purposes.
7/26/2024, 10:56 AM
Summary of Bill S 4774
Bill 118 s 4774, also known as the "PFAS Health Effects Guidance Act," aims to address the health effects of per- and polyfluoroalkyl substances (PFAS) by requiring the periodic issuance of updated clinical guidance. PFAS are a group of man-made chemicals that have been linked to various health issues, including cancer, immune system disorders, and developmental delays.
The bill mandates that the Department of Health and Human Services (HHS) regularly update and issue clinical guidance on how to address the health effects of PFAS exposure. This guidance will be based on the latest scientific research and will provide healthcare providers with information on how to diagnose, treat, and prevent health issues related to PFAS exposure.
In addition to providing clinical guidance, the bill also requires HHS to conduct research on the health effects of PFAS and to collaborate with other federal agencies, state and local governments, and stakeholders to address the issue. This collaborative approach is intended to ensure that the most up-to-date information and resources are available to healthcare providers and the public. Overall, the PFAS Health Effects Guidance Act seeks to improve public health by ensuring that healthcare providers have the information and resources they need to effectively address the health effects of PFAS exposure. By requiring the periodic issuance of updated clinical guidance and promoting collaboration among various stakeholders, the bill aims to protect individuals and communities from the harmful effects of PFAS.
The bill mandates that the Department of Health and Human Services (HHS) regularly update and issue clinical guidance on how to address the health effects of PFAS exposure. This guidance will be based on the latest scientific research and will provide healthcare providers with information on how to diagnose, treat, and prevent health issues related to PFAS exposure.
In addition to providing clinical guidance, the bill also requires HHS to conduct research on the health effects of PFAS and to collaborate with other federal agencies, state and local governments, and stakeholders to address the issue. This collaborative approach is intended to ensure that the most up-to-date information and resources are available to healthcare providers and the public. Overall, the PFAS Health Effects Guidance Act seeks to improve public health by ensuring that healthcare providers have the information and resources they need to effectively address the health effects of PFAS exposure. By requiring the periodic issuance of updated clinical guidance and promoting collaboration among various stakeholders, the bill aims to protect individuals and communities from the harmful effects of PFAS.
Current Status of Bill S 4774
Bill S 4774 is currently in the status of Bill Introduced since July 25, 2024. Bill S 4774 was introduced during Congress 118 and was introduced to the Senate on July 25, 2024. Bill S 4774's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of July 25, 2024
Bipartisan Support of Bill S 4774
Total Number of Sponsors
1Democrat Sponsors
1Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
2Democrat Cosponsors
0Republican Cosponsors
2Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill S 4774
Primary Policy Focus
Alternate Title(s) of Bill S 4774
A bill to provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), and for other purposes.
A bill to provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), and for other purposes.
Comments
Sponsors and Cosponsors of S 4774
Latest Bills
Honduras Expropriation Accountability Act
Bill HR 7807March 24, 2026
Debt-to-GDP Transparency and Stabilization Act
Bill HR 7808March 24, 2026
Responsible Containment Reauthorization Act
Bill HR 7811March 24, 2026
BLS Act
Bill HR 7804March 24, 2026
Direct File Act of 2026
Bill HR 7806March 24, 2026
Red Star Service Banner Act
Bill HR 7815March 24, 2026
Lowering Student Loans Act
Bill HR 7810March 24, 2026
HEALTHY BRAINS Act of 2026
Bill HR 7779March 24, 2026
Parity for Tribal Educators Act
Bill HR 7781March 24, 2026
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by Bureau of Consumer Financial Protection relating to the withdrawal of the rule relating to "Debt Collection Practices (Regulation F); Deceptive and Unfair Collection of Medical Debt".
Bill SJRES 141March 24, 2026

